CN1268053A - 包含阿伐他汀和抗高血压药的联合疗法 - Google Patents

包含阿伐他汀和抗高血压药的联合疗法 Download PDF

Info

Publication number
CN1268053A
CN1268053A CN98808463A CN98808463A CN1268053A CN 1268053 A CN1268053 A CN 1268053A CN 98808463 A CN98808463 A CN 98808463A CN 98808463 A CN98808463 A CN 98808463A CN 1268053 A CN1268053 A CN 1268053A
Authority
CN
China
Prior art keywords
pharmaceutical composition
pharmaceutically acceptable
compound
antihypertensive drug
prepared according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN98808463A
Other languages
English (en)
Chinese (zh)
Inventor
R·A·D·斯科特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of CN1268053A publication Critical patent/CN1268053A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Iron Core Of Rotating Electric Machines (AREA)
CN98808463A 1997-08-29 1998-08-11 包含阿伐他汀和抗高血压药的联合疗法 Pending CN1268053A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5727697P 1997-08-29 1997-08-29
US60/057,276 1997-08-29

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CNA031430937A Division CN1473567A (zh) 1997-08-29 1998-08-11 包含阿伐他汀和抗高血压药的联合疗法
CNA031430929A Division CN1473566A (zh) 1997-08-29 1998-08-11 包含阿伐他汀和抗高血压药的联合疗法

Publications (1)

Publication Number Publication Date
CN1268053A true CN1268053A (zh) 2000-09-27

Family

ID=22009602

Family Applications (3)

Application Number Title Priority Date Filing Date
CN98808463A Pending CN1268053A (zh) 1997-08-29 1998-08-11 包含阿伐他汀和抗高血压药的联合疗法
CNA031430929A Pending CN1473566A (zh) 1997-08-29 1998-08-11 包含阿伐他汀和抗高血压药的联合疗法
CNA031430937A Pending CN1473567A (zh) 1997-08-29 1998-08-11 包含阿伐他汀和抗高血压药的联合疗法

Family Applications After (2)

Application Number Title Priority Date Filing Date
CNA031430929A Pending CN1473566A (zh) 1997-08-29 1998-08-11 包含阿伐他汀和抗高血压药的联合疗法
CNA031430937A Pending CN1473567A (zh) 1997-08-29 1998-08-11 包含阿伐他汀和抗高血压药的联合疗法

Country Status (41)

Country Link
US (2) US20020099046A1 (https=)
EP (1) EP1009400B1 (https=)
JP (2) JP2001514223A (https=)
KR (3) KR20010022477A (https=)
CN (3) CN1268053A (https=)
AP (1) AP1191A (https=)
AR (1) AR016399A1 (https=)
AT (1) ATE285767T1 (https=)
AU (1) AU740424B2 (https=)
BG (1) BG64724B1 (https=)
BR (1) BR9811556A (https=)
CA (1) CA2296723A1 (https=)
CO (1) CO4970724A1 (https=)
DE (1) DE69828413T2 (https=)
DZ (1) DZ2595A1 (https=)
EA (1) EA200000012A1 (https=)
EG (1) EG24678A (https=)
ES (1) ES2234134T3 (https=)
GT (1) GT199800126A (https=)
HR (1) HRP980474A2 (https=)
HU (1) HUP0004318A3 (https=)
ID (1) ID24118A (https=)
IL (2) IL133962A0 (https=)
IS (1) IS5341A (https=)
MA (1) MA26536A1 (https=)
MY (1) MY121008A (https=)
NO (1) NO323987B1 (https=)
NZ (2) NZ502280A (https=)
OA (1) OA11291A (https=)
PA (1) PA8457901A1 (https=)
PE (1) PE107099A1 (https=)
PL (1) PL339091A1 (https=)
PT (1) PT1009400E (https=)
SA (1) SA98190603B1 (https=)
SK (1) SK1432000A3 (https=)
TN (1) TNSN98155A1 (https=)
TR (1) TR200000563T2 (https=)
UY (1) UY25155A1 (https=)
WO (1) WO1999011260A1 (https=)
YU (1) YU2000A (https=)
ZA (1) ZA987839B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105232555A (zh) * 2015-11-19 2016-01-13 哈尔滨圣吉药业股份有限公司 一种替米沙坦/瑞舒伐他汀复方制剂及其制备方法
CN108156807A (zh) * 2015-06-30 2018-06-12 韩美药品株式会社 含有氨氯地平、氯沙坦和瑞舒伐他汀的药物复合制剂

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69333624T2 (de) 1992-05-19 2005-09-15 Novogen Research Pty. Ltd., North Ryde Verwendung von isoflavon phyto-östrogen extrakten von soja oder klee
US6262277B1 (en) 1994-09-13 2001-07-17 G.D. Searle And Company Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US6642268B2 (en) 1994-09-13 2003-11-04 G.D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
AUPO203996A0 (en) 1996-08-30 1996-09-26 Novogen Research Pty Ltd Therapeutic uses
GT199800127A (es) * 1997-08-29 2000-02-01 Combinaciones terapeuticas.
BR9815745A (pt) * 1998-03-17 2000-11-14 Warner Lambert Co Combinações de inibidor de metaloproteinase de matriz estatina
US6489366B1 (en) 1998-12-23 2002-12-03 G. D. Searle, Llc Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acid derivatives for cardiovascular indications
AU2007200367B2 (en) * 1999-02-06 2010-04-08 Astrazeneca Ab Use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy
GB0001662D0 (en) 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
PL353199A1 (en) 1999-08-30 2003-11-03 Aventis Pharma Deutschland Gmbh Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events
AUPQ266199A0 (en) 1999-09-06 1999-09-30 Novogen Research Pty Ltd Compositions and therapeutic methods involving isoflavones and analogues thereof
DE19944803A1 (de) * 1999-09-20 2001-03-29 Bayer Ag Kombination von Dihydropyridinverbindungen und HMG-CoA-Reduktase-Inhibitoren und ihre Verwendung in Arzneimitteln
ATE309807T1 (de) 1999-09-24 2005-12-15 Vasogen Ireland Ltd Zusammensetzung zur behandlung von atherosklerose,welche ein statin und ex-vivo behandeltes blut enthält
FR2803525B1 (fr) * 2000-01-06 2002-05-03 Sod Conseils Rech Applic Inhibiteur de la transduction des signaux des proteines g heterotrimeriques associe a un agent anti-hypertenseur dans le traitement de l'hypertension arterielle
AR030414A1 (es) * 2000-04-03 2003-08-20 Astrazeneca Ab Combinacion farmaceutica que comprende un beta bloqueante y un inhibidor de hmg-coa reductasa , formulacion farmaceutica, equipo transportable de partes , uso de esta combinacion y de esta formulacion para preparar medicamentos
GB2361185A (en) 2000-04-10 2001-10-17 Nicholas J Wald Pharmaceutical formulation for the prevention of cardiovascular disease
SE0002354D0 (sv) * 2000-06-22 2000-06-22 Astrazeneca Ab New formulation
BR0112665A (pt) 2000-07-19 2003-06-24 Novartis Ag Sais
WO2002017913A1 (en) * 2000-08-30 2002-03-07 Sankyo Company, Limited Medicinal compositions for preventing or treating heart failure
US7018649B2 (en) * 2000-10-23 2006-03-28 Euro-Celtique, S.A. Felodipine transdermal device and methods
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
AUPR255401A0 (en) * 2001-01-16 2001-02-08 Novogen Research Pty Ltd Regulation of lipids and/or bone density and compositions therefor
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
AR035533A1 (es) 2001-01-26 2004-06-02 Schering Corp Uso de por lo menos un inhibidor de la absorcion de los esteroles o sus sales, solvatos, prodrogas farmaceuticamente aceptables o mezclas de los mismos para la preparacion de un medicamento para el tratamiento de la sitosterolemia, composiciones farmaceuticas, el uso de dichas composiciones para la
IL156445A0 (en) 2001-01-26 2004-01-04 Schering Corp Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
AUPR363301A0 (en) 2001-03-08 2001-04-05 Novogen Research Pty Ltd Dimeric isoflavones
UA76475C2 (en) * 2001-07-19 2006-08-15 Pharmacia Corp Combination of eplerenon and hmg co-a reductase inhibitor and its use for treatment and/or prophylaxis of pathologic condition in cardiovascular system
PE20030324A1 (es) * 2001-07-31 2003-04-03 Warner Lambert Co Composiciones farmaceuticas de amlodipina y atorvastatina
US6852737B2 (en) * 2001-08-06 2005-02-08 Recordati Ireland Limited Crude and crystalline forms of lercanidipine hydrochloride
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
MXPA04002573A (es) 2001-09-21 2004-06-18 Schering Corp Tratamiento de xantoma con derivados de azetidinona como inhibidores de la absorcion de esterol.
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
BR0306643A (pt) 2002-01-17 2004-10-19 Pharmacia Corp Novos compostos de hidroxi alquil/aril ou ceto tiepina como inibidores do transporte co-dependente de ácido biliar-sódio apical
CA2490636A1 (en) * 2002-06-20 2003-12-31 The Governors Of The University Of Alberta Dichloroacetate in combination with cardioprotective or hemodynamic drugs
JP2005533822A (ja) * 2002-06-27 2005-11-10 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド 臭化水素酸カルベジロール
KR101468827B1 (ko) * 2002-06-27 2014-12-03 스미스클라인 비이참 (코르크) 리미티드 카베딜롤 인산염 및(또는) 그의 용매화물, 상응하는 조성물, 및(또는) 치료 방법
US20040053842A1 (en) * 2002-07-02 2004-03-18 Pfizer Inc. Methods of treatment with CETP inhibitors and antihypertensive agents
US7071210B2 (en) * 2002-07-02 2006-07-04 Pfizer Inc. CETP inhibitors in combination with antihypertensive agents and uses thereof
GB0221579D0 (en) * 2002-09-17 2002-10-23 Pfizer Ltd Combinations of atorvastatin and, adrenergic receptor antagonists
JP2006504800A (ja) * 2002-10-16 2006-02-09 レコーダチ アイルランド リミテッド リシノプリル／レルカニジピンの組み合わせ治療
WO2004043457A1 (en) 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
CA2517572C (en) 2003-03-07 2011-12-13 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
JP2006519869A (ja) 2003-03-07 2006-08-31 シェーリング　コーポレイション 置換アゼチジノン化合物、置換アゼチジノン化合物を調製するためのプロセス、それらの処方物および使用
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
EP1601668B1 (en) 2003-03-07 2008-08-27 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
JP2007512350A (ja) * 2003-11-25 2007-05-17 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド カルベジロール組成物の治療および送達方法
US8734850B2 (en) * 2003-11-25 2014-05-27 Flamel Technologies Oral medicinal product with modified release of at least one active principle in multimicrocapsular form
EP1686986A4 (en) * 2003-11-25 2009-05-27 Sb Pharmco Inc CARVEDILOL SALTS, CORRESPONDING COMPOSITIONS, METHODS OF ADMINISTRATION AND / OR TREATMENT
KR20050092519A (ko) * 2004-03-16 2005-09-22 화이자 인코포레이티드 아토르바스타틴 및 α1-아드레날린성 수용체 길항제의 조합
WO2005099700A1 (en) * 2004-04-06 2005-10-27 Merck & Co., Inc. Methods for the treatment of hypertension
ES2282062T1 (es) 2004-06-04 2007-10-16 Teva Pharmaceutical Industries Ltd. Composicion farmaceutica que contiene irbesartan.
EP1781265B1 (en) 2004-08-25 2010-04-07 Essentialis, Inc. Pharmaceutical formulations of potassium atp channel openers and uses thereof
KR20070111468A (ko) * 2005-02-17 2007-11-21 키에시 파르마슈티시 엣스. 피. 에이. 마니디핀과 스타틴의 치료용 복합물
CA2645281A1 (en) 2006-03-29 2007-10-04 Kowa Co., Ltd. Triglyceride-lowering agent and hyperinsulinism-ameliorating agent
US8642083B2 (en) * 2006-10-30 2014-02-04 Hanall Biopharma Co., Ltd. Controlled release complex composition comprising angiotensin-II-receptor blockers and HMG-CoA reductase inhibitors
US20110117194A1 (en) 2008-04-29 2011-05-19 Hanall Biopharma Co., Ltd. Pharmaceutical formulation containing angiotensin-ii receptor blocker
CZ2008740A3 (cs) * 2008-11-24 2010-01-06 Zentiva, A.S. Pevná farmaceutická kompozice s úcinnými látkami atorvastatinem a telmisartanem
MY173823A (en) * 2009-01-23 2020-02-24 Hanmi Science Co Ltd Solid pharmaceutical composition comprising amlodipine and losartan and process for producing same
SI23149A (sl) * 2009-09-21 2011-03-31 Silverstone Pharma Nove benzatinske soli ACE inhibitorjev, postopek za njihovo pripravo in njihova uporaba za zdravljenje kardiovaskularnih bolezni
RU2481124C1 (ru) * 2011-10-27 2013-05-10 Общество с ограниченной ответственностью "ВАЛЕНТА ИНТЕЛЛЕКТ" Фармацевтическая комбинация из аторвастатина и ницерголина для профилактики или лечения нарушений мозгового кровообращения
CN102671198A (zh) * 2011-12-17 2012-09-19 东莞达信生物技术有限公司 一种降压降脂复方药及其制备方法
KR20140028971A (ko) * 2012-08-31 2014-03-10 한미약품 주식회사 아토바스타틴, 이르베살탄 및 탄산마그네슘을 포함하는 이층정 복합제제
WO2014142521A1 (ko) * 2013-03-12 2014-09-18 주식회사 엘지생명과학 발사르탄 및 로수바스타틴 칼슘을 포함하는 복합 제제 및 이의 제조방법
CN104173420A (zh) * 2013-05-20 2014-12-03 广州诺氏刘生物科技有限公司 一种治疗急性肾衰竭的药物
WO2016065103A1 (en) 2014-10-23 2016-04-28 Arena Pharmaceuticals, Inc. Method of treating conditions related to the pgi2 receptor
FR3040303B1 (fr) * 2015-08-27 2019-04-05 Les Laboratoires Servier Suivi Par Sabine Goudeau-Wenger Composition pharmaceutique comprenant un inhibiteur de la hmg-coa reductase et un inhibiteur eca
JP2019517482A (ja) * 2016-06-02 2019-06-24 アナ ファーマシューティカルズ， インコーポレイテッドＡｎａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 高カルシウム尿症及び腎結石症の治療方法及び治療用組成物
KR20240096848A (ko) 2017-01-25 2024-06-26 더 조지 인스티튜트 포 글로벌 헬스 고혈압의 치료를 위한 조성물
US12521380B2 (en) 2017-01-25 2026-01-13 The George Institute for Global Health Compositions for the treatment of hypertension
EP3977985B1 (en) 2017-03-01 2023-09-06 Arena Pharmaceuticals, Inc. Compositions comprising pgi2-receptor agonists and processes for the preparation thereof
WO2019222764A1 (en) 2018-05-16 2019-11-21 Arena Pharmaceuticals, Inc. Compositions comprising pgi2-receptor agonists and processes for the preparation thereof
MX2021001043A (es) * 2018-07-26 2021-04-12 The George Inst For Global Health Composiciones para el tratamiento de hipertension.
CN112826937B (zh) * 2021-03-25 2022-03-22 山东大学齐鲁医院 艾地苯醌与他汀类药物联用在防治动脉粥样硬化中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681893A (en) * 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5447922A (en) * 1994-08-24 1995-09-05 Bristol-Myers Squibb Company α-phosphonosulfinic squalene synthetase inhibitors
US5798375A (en) * 1995-07-03 1998-08-25 Sankyo Company, Limited Treatment of arteriosclerosis and xanthoma
WO1997016184A1 (en) * 1995-11-02 1997-05-09 Warner-Lambert Company Method and pharmaceutical composition for regulating lipid concentration

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108156807A (zh) * 2015-06-30 2018-06-12 韩美药品株式会社 含有氨氯地平、氯沙坦和瑞舒伐他汀的药物复合制剂
CN105232555A (zh) * 2015-11-19 2016-01-13 哈尔滨圣吉药业股份有限公司 一种替米沙坦/瑞舒伐他汀复方制剂及其制备方法

Also Published As

Publication number Publication date
JP2001514223A (ja) 2001-09-11
EA200000012A1 (ru) 2000-08-28
IL133962A0 (en) 2001-04-30
ZA987839B (en) 2000-02-28
PA8457901A1 (es) 2000-05-24
MY121008A (en) 2005-12-30
KR20010022477A (ko) 2001-03-15
UY25155A1 (es) 2000-12-29
GT199800126A (es) 2000-01-29
TR200000563T2 (tr) 2000-07-21
HRP980474A2 (en) 1999-06-30
HUP0004318A2 (hu) 2001-05-28
JP2005041875A (ja) 2005-02-17
IS5341A (is) 2000-01-14
AP9801332A0 (en) 1998-09-30
AR016399A1 (es) 2001-07-04
ES2234134T3 (es) 2005-06-16
BR9811556A (pt) 2000-08-22
CO4970724A1 (es) 2000-11-07
CN1473566A (zh) 2004-02-11
NO20000996D0 (no) 2000-02-28
NZ530630A (en) 2005-05-27
DE69828413T2 (de) 2005-12-08
AP1191A (en) 2003-07-19
BG64724B1 (bg) 2006-01-31
WO1999011260A1 (en) 1999-03-11
PE107099A1 (es) 1999-11-06
AU8458998A (en) 1999-03-22
KR20030015394A (ko) 2003-02-20
NO20000996L (no) 2000-04-27
AU740424B2 (en) 2001-11-01
OA11291A (en) 2003-08-25
EG24678A (en) 2010-04-27
CA2296723A1 (en) 1999-03-11
PL339091A1 (en) 2000-12-04
US20020099046A1 (en) 2002-07-25
NO323987B1 (no) 2007-07-30
US20030199492A1 (en) 2003-10-23
IL133962A (en) 2006-07-05
DE69828413D1 (de) 2005-02-03
ATE285767T1 (de) 2005-01-15
SA98190603B1 (ar) 2006-07-04
DZ2595A1 (fr) 2003-02-22
NZ502280A (en) 2002-11-26
CN1473567A (zh) 2004-02-11
MA26536A1 (fr) 2004-12-20
EP1009400A1 (en) 2000-06-21
EP1009400B1 (en) 2004-12-29
YU2000A (sh) 2002-12-10
ID24118A (id) 2000-07-06
BG104075A (en) 2000-09-29
TNSN98155A1 (fr) 2005-03-15
SK1432000A3 (en) 2000-12-11
HUP0004318A3 (en) 2002-10-28
KR20040106591A (ko) 2004-12-17
PT1009400E (pt) 2005-02-28

Similar Documents

Publication Publication Date Title
CN1268053A (zh) 包含阿伐他汀和抗高血压药的联合疗法
CN1268052A (zh) 含有氨氯地平和阿多伐他丁的治疗组合物
CN1117566C (zh) 包含氨氯地平和抑制素化合物的联合药物形式
US6262092B1 (en) Mutual salt of amlodipine and atorvastatin
HK1046282A1 (zh) 氨氯地平和阿托伐他汀的共同前体药物
KR20010033003A (ko) 스타틴-카르복시알킬에테르 병용 제제
US20040248948A1 (en) Combination therapy
CN1426299A (zh) 抗高血压剂和用途
HK1061807A (en) Combination therapy comprising atorvastatin and an antihypertensive agent
HK1061808A (en) Combination therapy comprising atorvastatin and an antihypertensive agent
HK1029288A (zh) 包含阿伐他汀和抗高血压药的联合疗法
HK1029530B (en) Combination pharmaceutical form comprising amlodipine and a statin compound
HK1029527A (en) Therapeutic combinations comprising amlodipin and atorvastatin
HK1109073A (en) Therapeutic combinations comprising amlodipin and atorvastatin
HK1055249A (en) Antihypertensive agents and use
HK1049162A (en) Mutual salt of amlodipine and atorvastatin
CZ2000319A3 (cs) Kombinační terapie zahrnující amlodipin a statinové sloučeniny
MXPA00002085A (en) Combination therapy comprising amlodipine and a statin compound

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1029288

Country of ref document: HK